Xencor Inc
XNCR11.610USD
+0.790+7.30%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
828.29M시가총액
손실P/E TTM
자세한 내용은 Xencor Inc 회사
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Inc 정보
종목 코드 XNCR
회사 이름Xencor Inc
상장일Dec 03, 2013
CEODahiyat (Bassil I)
직원 수250
유형Ordinary Share
회계 연도 종료Dec 03
주소465 N. Halstead St.
도시PASADENA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호91107
전화16263055900
웹사이트https://xencor.com/
종목 코드 XNCR
상장일Dec 03, 2013
CEODahiyat (Bassil I)
Xencor Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
224.60K
+5322.00%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+16209.00%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-3750.00%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+10693.00%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
+13686.00%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+10693.00%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
224.60K
+5322.00%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+16209.00%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-3750.00%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+10693.00%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
+13686.00%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+10693.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Royalties
21.00M
0.00%
Milestone
0.00
0.00%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Royalties
21.00M
0.00%
Milestone
0.00
0.00%
주식 보유 통계
마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
PRIMECAP Management Company
14.95%
BlackRock Institutional Trust Company, N.A.
14.82%
The Vanguard Group, Inc.
10.01%
RTW Investments L.P.
8.71%
EcoR1 Capital, LLC
8.60%
기타
42.90%
주주
주주
비율
PRIMECAP Management Company
14.95%
BlackRock Institutional Trust Company, N.A.
14.82%
The Vanguard Group, Inc.
10.01%
RTW Investments L.P.
8.71%
EcoR1 Capital, LLC
8.60%
기타
42.90%
주주 유형
주주
비율
Investment Advisor
56.73%
Investment Advisor/Hedge Fund
36.40%
Hedge Fund
18.64%
Research Firm
3.84%
Individual Investor
1.34%
Venture Capital
1.05%
Pension Fund
0.91%
Bank and Trust
0.36%
Sovereign Wealth Fund
0.08%
기관 주식 보유
마지막 업데이트: Wed, Jan 21
마지막 업데이트: Wed, Jan 21
보고 기간
기관 수
보유 주식
비율
변동
2026Q4
364
84.79M
119.03%
--
2025Q4
446
84.32M
118.08%
-5.51M
2025Q3
434
80.43M
112.65%
-6.04M
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
2023Q4
420
65.39M
107.20%
-1.62M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
PRIMECAP Management Company
10.68M
14.95%
+147.70K
+1.40%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.58M
14.82%
-92.56K
-0.87%
Sep 30, 2025
The Vanguard Group, Inc.
7.17M
10.04%
+80.65K
+1.14%
Nov 28, 2025
RTW Investments L.P.
6.22M
8.71%
+3.82M
+158.90%
Sep 30, 2025
EcoR1 Capital, LLC
6.14M
8.6%
--
--
Sep 30, 2025
BVF Partners L.P.
4.62M
6.47%
+1.88M
+68.58%
Oct 17, 2025
State Street Investment Management (US)
3.67M
5.14%
-143.78K
-3.77%
Sep 30, 2025
TCG Crossover Management, LLC
2.45M
3.43%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
1.73M
2.42%
+25.16K
+1.48%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.59M
2.23%
-191.61K
-10.76%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Genomics Immunology and Healthcare ETF
2.09%
Tema Oncology ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
Invesco NASDAQ Future Gen 200 ETF
0.97%
Invesco S&P SmallCap Health Care ETF
0.64%
ALPS Medical Breakthroughs ETF
0.43%
State Street SPDR S&P Biotech ETF
0.33%
Inspire Small/Mid Cap ESG ETF
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
더 보기
iShares Genomics Immunology and Healthcare ETF
비율2.09%
Tema Oncology ETF
비율1.16%
Virtus LifeSci Biotech Clinical Trials ETF
비율1.06%
Invesco NASDAQ Future Gen 200 ETF
비율0.97%
Invesco S&P SmallCap Health Care ETF
비율0.64%
ALPS Medical Breakthroughs ETF
비율0.43%
State Street SPDR S&P Biotech ETF
비율0.33%
Inspire Small/Mid Cap ESG ETF
비율0.3%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.15%
ProShares Ultra Nasdaq Biotechnology
비율0.15%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
